The impact of BNO 1030 on phagocytic activity of white blood cells in rats with type 1 diabetes mellitus
Journal Title: Міжнародний ендокринологічний журнал - Year 2017, Vol 13, Issue 5
Abstract
Background. In the pathogenesis of type 1 diabetes mellitus (DM1) and many of its complications, an important place belongs to a violation of the functional capacity of the immune system, which is the subject of numerous studies. Considering the effectiveness of immunomodulating therapy for DM1 and its complications, one of the most important problems is the search for new effective and harmless immunocorrecting agents with high pharmacological activity. The purpose of this study was to evaluate the effect of the phytopreparation BNO 1030 on the phagocytic activity of blood leukocytes in rats with DM1. Materials and methods. Experimental DM1 in rats was induced by a single intraperitoneal injection of streptozotocin. The percentage of phagocytic cells and macrophage uptake of live fluorescent bacteria in the samples were determined using fluorescent live bacteria Escherichia coli. Results. The effect of the drug BNO 1030 on the phagocytic activity of white blood cells with DM1 in rats was investigated. Under hyperglycemia it was found changes in the redistribution of the main types of leukocytes, namely granulocytes and agranulocytes. The administration of the drug BNO 1030 to both control and diabetic animals resulted in an increase in the number of agranulocytes, which may indicate a modulating effect of the drug on the immune system of animals. Under these conditions, phagocytic activity of leukocytes was decreased as phagocytic number in group of diabetic rats was reduced by 42 % in comparison with group of control animals. BNO 1030 administration to diabetic rats caused an increase of phagocyte number by 24 % compared to the group of diabetic animals. These changes, in turn, are also accompanied by a decrease of phagocytic index as in diabetes, and when drug was administered to experimental groups, indicating disorders in nonspecific cellular immune system. Conclusions. BNO 1030 due to its immunomodulatory effect is effective in the treatment of DM1 and its comorbidity with other chronic diseases.
Authors and Affiliations
Yu. V. Gavrylenko
Keywords
Related Articles
- EP ID EP240175
- DOI 10.22141/2224-0721.13.5.2017.110028
- Views 58
- Downloads 0
The effectiveness of methylcobalamin in the complex treatment of diabetic peripheral neuropathy
Background. Diabetic neuropathy is the most common complication of diabetes mellitus (DM), found in 30–90 % of patients. The relevance of the study is due to the prevalence of diabetic neuropathy, as well as assessing th...
Immunomodulatory Therapy of Chronic Fatigue Syndrome Associated with Metabolic Syndromе
In 16 patients with chronic obstructive pulmonary disease with metabolic syndrome and chronic fatigue syndrome, we have studied the effect of combined use of noophen and broncho-munal based on the evaluation of clinical...
Acute stent thrombosis in myocardial infarction complicated by cardiogenic shock in the presence of type 2 diabetes mellitus
Background. Acute stent thrombosis is a rare, but life-threatening complication of coronary stenting. It occurs during percutaneous coronary intervention or within 24 hours after this procedure. The purpose of the study...
Diabetes Mellitus Induced by Exogenous Administration of Glucocorticoids
The questions of the diagnosis and treatment of steroid-induced diabetes mellitus are considered in the lecture.
Assessment of cardiovascular risk in patients with primary chronic gout combined with metabolic syndrome
Background. The purpose of the study is to ivestigate the frequency of metabolic syndrome (MS) and to assess the total cardiovascular risk in patients with primary chronic gout, depending on the presence of MS. Materials...